CITIC Securities Co., Ltd

Shenzhen Huitai Medical Equipment Co., Ltd

Verification opinions on the postponement of some fundraising projects and the adjustment of investment amounts

CITIC Securities Co., Ltd. (hereinafter referred to as "CITIC Securities" or the "Sponsor") as the sponsor of the initial public offering of shares and listing on the Science and Technology Innovation Board of Shenzhen Huitai Medical Device Co., Ltd. (hereinafter referred to as "Huitai Medical" or the "Company"), in accordance with the Administrative Measures for the Sponsorship Business of Securities Issuance and Listing, the Rules for the Listing of Stocks on the Science and Technology Innovation Board of the Shanghai Stock Exchange, the Measures for the Continuous Supervision of Listed Companies on the Science and Technology Innovation Board (for Trial Implementation) and the Regulatory Guidelines for Listed Companies No. 2 - Regulatory Requirements for the Management and Use of Funds Raised by Listed Companies" and other relevant provisions of laws and regulations, the postponement of the investment project and the adjustment of the investment amount of part of the funds raised by Huitai Medical's initial public offering of shares have been verified, and the verification situation is as follows:

First, the basic situation of the funds raised

According to the "Notice on Agreeing to Shenzhen Huitai" issued by the China Securities Regulatory Commission on December 7, 2020

In the reply to the registration of the initial public offering of shares of Medical Devices Co., Ltd. (Zheng Jian Xu Xu [2020] No. 3359), the company publicly issued 16.67 million RMB ordinary shares (A shares) to the public (par value of RMB 1 per share).

yuan), and was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange on January 7, 2021 (hereinafter referred to as the "Offering").

line"). The issue price of this offering is 74.46 yuan per share, and the total amount of funds raised in this offering is 1,241,248,200.00 yuan, and the net amount of funds raised after deducting the company's sponsorship and underwriting fees excluding value-added tax and other issuance expenses is 1,150,717,825.25 yuan. Lixin Certified Public Accountants (Special General Partnership) 2021

On January 4, the Capital Verification Report [2021] No. ZA10001 was issued to verify that the raised funds had been fully funded

The ministry is in place. Huitai Medical has carried out a special account storage of the raised funds, and signed relevant regulatory agreements with the sponsor and the commercial bank where the raised funds are deposited.

Second, the basic situation of the raised funds investment project

According to the "Prospectus for the Initial Public Offering of Shares of Shenzhen Huitai Medical Device Co., Ltd. and Listing on the Science and Technology Innovation Board" and the "Announcement of Shenzhen Huitai Medical Device Co., Ltd. on the Change of the Implementation Method, Adjustment of Investment Amount and New Fundraising and Investment Projects of Some Fundraising and Investment Projects" (Announcement No.: 2022-028), "Shenzhen Huitai

Announcement of Medical Devices Co., Ltd. on Adjusting the Investment Amount of Fund-raising Projects and Adding New Fund-raising Projects (Announcement No.: 2023-013) and Announcement of Shenzhen Huitai Medical Devices Co., Ltd. on Using Over-raised Funds and Own Funds to Invest in the Construction of New Projects (Announcement No.: 2023-044), the total amount of funds raised by the company's initial public offering of RMB ordinary shares (A shares) will be used to invest in the following projects after deducting the issuance fee:

Unit: 10,000 yuan

Serial No. Project Name Originally Expected to be Raised After Adjustment, it is planned to be put into fundraising

Amount of funds The amount of funds

1 Industrialization and upgrading project of vascular interventional medical devices 36,761.00 32,761.00

2 R&D projects of vascular interventional medical devices 33,869.00 13,224.44

3 R&D project of new electrophysiological ablation mapping system - 14,111.00

4 Peripheral Vascular Interventional Programs - 6,533.56

5 Intelligent Manufacturing Base and Testing Center Project - 4,000.00

6 Replenishment of liquidity 13,419.00 13,419.00

7 Regional Headquarters Center - 33,732.02

Total 84,049.00 117,781.02

Note: The net amount of funds raised by the company was RMB1150.7178 million, of which the over-raised funds were RMB310.2278 million

Yuan; The amount of funds to be raised in the regional headquarters center project is 337.3202 million yuan, which includes the financial income and interest income of the raised funds.

3. The postponement of the investment project of the raised funds and the adjustment of the investment amount

(1) "Vascular interventional medical device R&D project" postponed and adjusted the scale of investment

As of September 30, 2024, the company's "Vascular Interventional Medical Device R&D Project" has been invested cumulatively

118,294,200 yuan was raised. During the implementation of the project, the original test plan was re-optimized due to the fact that the results of the first animal test of some products did not meet expectations, resulting in the project progress falling short of expectations.

After careful consideration by the company's management, combined with factors such as R&D progress, market demand, and efficiency of the use of raised funds, it was decided to adjust the investment progress of the "Vascular Interventional Medical Device R&D Project", which was postponed from the date of the original planned project to December 2025, and the total amount of committed investment of the "Vascular Interventional Medical Device R&D Project" was reduced from RMB 132.2444 million to RMB 129.2444 million. The reduction amount is 3.00 million yuan.

The postponement and adjustment of the investment amount of this project are as follows:

Investment progress postponement Total project investment Adjustment of the investment amount of raised funds

Amount adjustments

Project Name Original Plan Item Adjusted Project Original Plan Investment Adjusted Proposed Original Plan Raised After Adjustment

The goal is to reach the predetermined amount of funds The total amount of funds invested is proposed to be funded

Availability: Date of use (10,000 yuan) (10,000 yuan) Amount of funds Total amount of investment

Status Date Period (10,000 yuan) (10,000 yuan)

Vascular intervention

Medical devices 2024 9 2025 12 13,224.44 12,924.44 13,224.44 12,924.44

Machinery R&D project month

eye

The specific composition adjustments are as follows:

Serial No. Name of Project or Cost Investment Amount Before Adjustment (10,000 Yuan) Investment Amount After Adjustment (10,000 Yuan)

1 Basic reserve 773.00 773.00

2 R&D expenses 12,451.44 12,151.44

2.1 R&D personnel salary 5,724.00 5,724.00

2.2 Other R&D expenses 6,727.44 6,427.44

The total investment of the project is 13,224.44 12,924.44

The adjustment of the total amount of funds committed to the "Vascular Interventional Medical Device R&D Project" is mainly based on the requirements of the project, and the company has re-optimized the original test plan, and the optimized plan is expected to reduce part of the R&D investment. In addition to the above adjustments, other matters of the "Vascular Interventional Medical Device R&D Project" will not be adjusted.

(2) The total amount of investment expected to be used to raise funds for the "Intelligent Manufacturing Base and Testing Center Project" will be adjusted

On April 6, 2023, the company held the third meeting of the second board of directors and the third meeting of the second board of supervisors

At the meeting, the "Proposal on Adjusting the Investment Amount of Fund-raising Projects and New Fund-raising Projects" was deliberated and approved, and it was agreed to invest in the new project "Intelligent Manufacturing Base and Testing Center Project", with a total construction area of 54,895.20 square meters, which is mainly used to meet the needs of subsequent enterprise product production and related reserves and needs, including seven factories and others

Related supporting facilities. The Company made a corresponding disclosure on April 7, 2023.

As of October 31, 2024, the "Intelligent Manufacturing Base and Testing Center Project" has been cumulatively fundraised

The raised capital was 40.3649 million yuan (including financial income and interest income from raised funds). Considering the current progress of the fund-raising project, in order to improve the efficiency of the use of the raised funds and help the development of the company's main business, after careful research and demonstration, the project will increase the investment of the raised funds to be used by 19.654 million yuan.

After this adjustment, the total investment of the project is expected to remain unchanged at 300 million yuan, and the total investment is expected to increase from 40 million yuan to 59.654 million yuan

The wealth management income and interest income of the raised funds as of September 30, 2024 in the "special fund collection account" were 1,665.40

10,000 yuan, totaling 19.654 million yuan.

The total amount of investment expected to be raised in this project is as follows:

Adjustment of the total investment amount of the project Adjustment of the investment amount of the raised funds

Project Name Original Plan Investment Total Investment After Adjustment Original Plan to Raise Funds Adjusted Funds to be raised

Amount (10,000 yuan) Amount (10,000 yuan) Investment amount The total amount of money to be invested

(10,000 yuan) (10,000 yuan)

Intelligent manufacturing base and inspection 30,000.00 30,000.00 4,000.00 5,965.40

Test Center Project

The specific composition adjustments are as follows:

Preface Project or Cost Name Investment Amount Before Adjustment (10,000 Yuan) Adjusted Investment Amount (10,000 Yuan)

Claim

1 Project construction cost 27,000.00 27,000.00

1.1 Civil works 19,500.00 19,500.00

(with raised funds 4,000) (with raised funds 5,965.40)

1.2 Equipment purchase and safety 7,500.00 7,500.00

feign

2 Basic Allowance 3,000.00 3,000.00

The total investment of the project is 30,000.00 30,000.00

In addition to the above adjustments, other matters of the "Intelligent Manufacturing Base and Testing Center Project" will not be adjusted.

In order to ensure the implementation and management of the new project, the company intends to provide the newly raised funds of 19.654 million yuan to its wholly-owned subsidiary, Hunan Epte Medical Device Co., Ltd., in the form of interest-bearing loans for the implementation of the project. The term of the loan shall be calculated from the date of actual borrowing, and the interest rate of the loan shall be implemented with reference to the bank loan interest rate of the same period. The board of directors of the company proposes to the general meeting of shareholders of the company to authorize the management of the company to implement the loan according to the progress of the project.

Fourth, the impact of this postponement and adjustment on the company

The postponement of part of the company's raised funds investment project and the adjustment of the investment amount are prudent decisions made by the company according to the actual implementation of the relevant fund-raising projects and the actual construction needs, which is conducive to accelerating the fundraising

The speed of the use of raised funds, improve the efficiency of the use of funds, do not involve substantial changes in the construction content of the fund-raising and investment projects, there is no change or disguised change in the investment direction of the raised funds, will not have a substantial impact on the implementation of the fund-raising projects, in line with the relevant laws and regulations, normative documents and the provisions of the company's "Measures for the Management of Raised Funds", there is no harm to the interests of shareholders, in line with the company's long-term development plan and the long-term interests of shareholders.

5. Procedures for the review of the performance

(1) Deliberations of the Board of Directors

On December 12, 2024, the company held the 20th meeting of the second board of directors to deliberate and approve the "Guan

Proposal on the postponement and adjustment of the investment amount of some fund-raising investment projects", agreed to the company's postponement and adjustment of the investment amount of some fund-raising projects.

The matter still needs to be submitted to the general meeting of shareholders of the company for deliberation.

(2) The deliberations of the board of supervisors

On December 12, 2024, the company held the 17th meeting of the second board of supervisors to deliberate and approve the "Guan

Proposal on the postponement and adjustment of the investment amount of some fund-raising investment projects", agreed to the company's postponement and adjustment of the investment amount of some fund-raising projects.

8. Sponsor verification opinions

Upon verification, the Sponsor is of the view that:

The relevant decision-making and approval procedures for the implementation progress and adjustment of the investment amount of some of Huitai Medical's fund-raising investment projects comply with the relevant laws and regulations such as the "Regulatory Guidelines for Listed Companies No. 2 - Regulatory Requirements for the Management and Use of Raised Funds by Listed Companies (Revised in 2022)", "Self-Regulatory Guidelines for Listed Companies on the Science and Technology Innovation Board of the Shanghai Stock Exchange No. 1 - Standardized Operation" and other relevant laws and regulations, as well as the company's "Administrative Measures for the Use of Raised Funds", and there is no change or disguised change in the investment direction of raised funds and damage to the interests of shareholders. In summary, the sponsor has no objection to the postponement of the company's part of the raised funds investment project and the adjustment of the investment amount.

(No text below)

(There is no text on this page, it is the signed and stamped page of the "Verification Opinions of CITIC Securities Co., Ltd. on the Postponement and Adjustment of Investment Amount of Some Fund-raising Projects of Shenzhen Huitai Medical Device Co., Ltd.")

Sponsor Representative:

Sun Yanlin, Zhao Yan

CITIC Securities Co., Ltd

YYYYYYYYYYYYYYYYY